BMKDF Stock Biomark Diagnostics (BMKDF, $0.25) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 18, 2025

GET DAILY SIGNALS

Get AI intraday signals

BMKDF - Biomark Diagnostics Inc.

MACD signal

View

Odds of UP Trend

Price: $0.2477

Daily change: +$0.0218 (+9.65%)

Daily volume: 2.5K

Capitalization: $26.2M

Industry: Medical Specialties

This is a Bullish indicator signaling BMKDF's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 51 similar cases where BMKDF's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:

BMKDF's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for BMKDF turned positive on November 18, 2025. Looking at past instances where BMKDF's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where BMKDF's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 18, 2025. You may want to consider a long position or call options on BMKDF as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

BMKDF moved above its 50-day moving average on November 18, 2025 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

BMKDF broke above its upper Bollinger Band on November 18, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BMKDF entered a downward trend on October 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMKDF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMKDF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.397) is normal, around the industry mean (11.917). P/E Ratio (0.000) is within average values for comparable stocks, (129.232). BMKDF's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.872). BMKDF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). BMKDF's P/S Ratio (212.766) is very high in comparison to the industry average of (9.613).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.